Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions.
Treatments based on molecular determinants are likely to be increasingly explored in the future. Future challenges will include ensuring that molecular determinants are identified as novel chemotherapeutic agents are being developed, enabling rationale therapeutics. Clinical trials will then enrich patients with the molecular determinants, potentially increasing response rates and survival in a specific group of patients who express this molecular determinant. It is hoped that this patient-specific 'individualized cocktails' will substantially improve response rates and survival.